Today’s Stocks: Varonis Systems, Inc. (NASDAQ:VRNS), eLong Inc. (NASDAQ:LONG), Canadian Solar Inc. (NASDAQ:CSIQ), Vical Incorporated (NASDAQ:VICL), Western Refining Logistics, LP (NYSE:WNRL)

Varonis Systems, Inc. (NASDAQ:VRNS) belongs to Technology sector. Its net profit margin is -22.50% and weekly performance is 5.07%. On last trading day company shares ended up $23.44. Varonis Systems, Inc. (NASDAQ:VRNS) distance from 50-day simple moving average (SMA50) is 4.83%. Zacks upgraded shares of Varonis Systems, Inc. (NASDAQ:VRNS)from a sell rating to a hold rating in a research note issued to investors on Tuesday.

eLong Inc. (NASDAQ:LONG) shares increased 18.13% in last trading session and ended the day at $15.05. LONG Gross Margin is 58.70% and its return on assets is -15.50%. eLong Inc. (NASDAQ:LONG) quarterly performance is -10.26%.On 8 June, eLong Inc. (NASDAQ:LONG) announced the appointment of Mr. Hao Jiang as its Chief Executive Officer.

On 09 July, Canadian Solar Inc. (NASDAQ:CSIQ) shares increased 4.35% and was closed at $25.64. CSIQ EPS growth in last 5 year was 46.90%. Canadian Solar Inc. (NASDAQ:CSIQ) year to date (YTD) performance is 5.99%. On 24 June, Canadian Solar Inc. (NASDAQ:CSIQ) has concluded the sale of a 10 megawatt (“MW”) power plant situated in Belleville, Ontario, to an affiliate of BluEarth Renewables Inc., a private independent renewable power producer. The transaction is valued at $53 million (C$65 million).

Vical Incorporated (NASDAQ:VICL) shares moved down -0.14% in last trading session and ended the day at $0.70. VICL Gross Margin is 30.50% and its return on assets is -28.60%. Vical Incorporated (NASDAQ:VICL) quarterly performance is -25.64%. On 22 June, Vical Incorporated (NASDAQ:VICL) announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients. The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent (gD) vaccine and a bivalent (gD + UL46) vaccine, each formulated with Vical’s proprietary Vaxfectin® adjuvant.

Western Refining Logistics, LP (NYSE:WNRL) shares increased 2.23% in last trading session and ended the day at $29.37. WNRL Gross Margin is 7.10% and its return on assets is 17.60%. Western Refining Logistics, LP (NYSE:WNRL) quarterly performance is 0.53%.Western Refining Logistics, LP (NYSE:WNRL) and its wholly-owned subsidiary WNRL Finance Corp., announced the completion of the exchange offer relating to their 71/2% Senior Notes due 2023 (the “Notes”).

Leave a Reply

Your email address will not be published. Required fields are marked *